Compass Therapeutics Inc.

CMPX remains in Stage 4 decline with price below declining EMAs and no base development. Long- and medium-term structures are bearish, while short-term timing is neutral as price consolidates near the flush‐low. Execution should be deferred until rallies into the broken EMA zone for selective trimming.

• ↑Tevesimig achieved 17.1% overall response rate and >20% survival, outperforming controls
• ↑Analyst consensus is Moderate Buy with $12.25 target implying 425.8% upside
• ↓Earnings Yield of –2.38% and weak profitability score signal financial strain